Drugs / Decitabine and Cedazuridine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03418038 Background | Mar 2018 → Feb 2031 expected | Hodgkins lymphoma, chronic myelomonocytic leukemia, clonal hematopoiesis, diffuse large B-cell lymphoma +1 | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine and Cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03418038 ↗ |
| Route | Oral | “Given PO” NCT03418038 ↗ |